Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination
Krystallenia Paniskaki, Moritz Anft, Toni Luise Meister, Corinna Marheinecke, Stephanie Pfaender, Sarah Skrzypczyk, Felix S. Seibert, Constantin J. Thieme, Margarethe Konik, Sebastian Dolff, Olympia E. Anastasiou, Bodo Hölzer, Ulf Dittmer, Christine Queren, Lutz Fricke, Hana Rohn, Timm H. Westhoff, Oliver Witzke, Ulrik Stervbo, Toralf Roch, Nina Babel
Abstract
SARS-CoV-2 variants of concern (VOCs) can trigger severe endemic waves and vaccine breakthrough infections (VBI). We analyzed the cellular and humoral immune response in 8 patients infected with the alpha variant, resulting in moderate to fatal COVID-19 disease manifestation, after double mRNA-based anti-SARS-CoV-2 vaccination. In contrast to the uninfected vaccinated control cohort, the diseased individuals had no detectable high-avidity spike (S)-reactive CD4+ and CD8+ T cells against the alpha variant and wild type (WT) at disease onset, whereas a robust CD4+ T-cell response against the N- and M-proteins was generated. Furthermore, a delayed alpha S-reactive high-avidity CD4+ T-cell response was mounted during disease progression. Compared to the vaccinated control donors, these patients also had lower neutralizing antibody titers against the alpha variant at disease onset. The delayed development of alpha S-specific cellular and humoral immunity upon VBI indicates reduced immunogenicity against the S-protein of the alpha VOC, while there was a higher and earlier N- and M-reactive T-cell response. Our findings do not undermine the current vaccination strategies but underline a potential need for the inclusion of VBI patients in alternative vaccination strategies and additional antigenic targets in next-generation SARS-CoV-2 vaccines.